Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Recbio Technology CoFRA:G93 24 PB Ratio is 5.20 as of Aug. 25, 2026, which is 32% above its 10-year median of 3.94. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review. Among 1,212 Biotechnology companies, Jiangsu Recbio Technology Co ranks worse than 71.53% on this metric.
Jiangsu Recbio Technology Co Ltd stock PB Ratio (=5.43) is close to 1-year high of 5.43.
The historical rank and industry rank for Jiangsu Recbio Technology Co's PB Ratio or its related term are showing as below:
FRA:G93'
s PB Ratio Range Over the Past 10 Years
Min: 2.85 Med: 3.94 Max: 5.43
Current: 5.43
During the past 7 years, Jiangsu Recbio Technology Co's highest PB Ratio was 5.43. The lowest was 2.85. And the median was 3.94.
FRA:G93's PB Ratio is ranked worse than 71.53% of 1212
companies
in the Biotechnology industry
Industry Median: 2.955
vs FRA:G93: 5.43
During the past 12 months, Jiangsu Recbio Technology Co's average Book Value Per Share Growth Rate was 6.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.30% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Jiangsu Recbio Technology Co was -31.30% per year. The lowest was -36.50% per year. And the median was -33.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jiangsu Recbio Technology Co PB Ratio Related Terms
Jiangsu Recbio Technology Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jiangsu Recbio Technology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Recbio Technology Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Recbio Technology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Recbio Technology Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jiangsu Recbio Technology Co (FRA:G93) has a PB Ratio of 5.20 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Recbio Technology Co and its competitors. This is 32% above median its historical median of 3.94. Over the past decade, Jiangsu Recbio Technology Co's PB Ratio has ranged from 2.85 to 5.43. According to the industry distribution chart, Jiangsu Recbio Technology Co ranks #867 out of 1212 companies in the Biotechnology industry, placing it in the top 71.5%.
Is Jiangsu Recbio Technology Co's PB Ratio too high?
Jiangsu Recbio Technology Co's current PB Ratio of 5.20 is 32% above median its 10-year median of 3.94. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 5.43. The Biotechnology industry median PB Ratio is 2.96. Jiangsu Recbio Technology Co's value of 5.20 is 76% above this industry median. Based on the distribution chart, Jiangsu Recbio Technology Co ranks #867 out of 1212 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Recbio Technology Co ranks #867 out of 1212 companies for PB Ratio. This places Jiangsu Recbio Technology Co in the lower half of its industry. The industry median PB Ratio is 2.96. Jiangsu Recbio Technology Co's value of 5.20 is 76% above this benchmark. Historically, Jiangsu Recbio Technology Co's own PB Ratio has ranged from 2.85 to 5.43 over the past decade. While the company's 10-year median is 3.94 vs. the industry median of 2.96, Jiangsu Recbio Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.96, based on 1,212 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Recbio Technology Co's current PB Ratio of 5.20 is 76% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Recbio Technology Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Recbio Technology Co's current PB Ratio is 5.20, which is 32% above median its own 10-year median of 3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current PB Ratio of 5.20. The current PB Ratio is 5.20, which is 32% above median its 10-year median of 3.94 and 76% above the Biotechnology industry median of 2.96. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current PB Ratio is 5.20 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score
Get the complete analysis for FRA:G93
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G93 has been successfully added to your 
